Tack'nTogs is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

FDA approves inhalation spray for severe equine asthma

Article-FDA approves inhalation spray for severe equine asthma

Shutterstock horse silhouette at sunset_shutterstock_62315617.jpg
Severe equine asthma, previously known as heaves, is associated with exposure to specific environmental triggers.

The Food & Drug Administration’s Center for Veterinary Medicine (CVM) announced April 13 that it has approved Aservo EquiHaler (ciclesonide inhalation spray) for the management of clinical signs associated with severe equine asthma in horses.

CVM said the Aservo EquiHaler has not been evaluated for safety and effectiveness in other equids, such as donkeys or mules.

Severe equine asthma — which has also been known in the past as heaves, chronic pulmonary obstructive disease (COPD) and recurrent airway obstruction (RAO) or summer pasture-associated obstructive pulmonary disease (SPAOPD) — results in the narrowing or obstruction of a horse’s airway passages, causing exercise intolerance, labored breathing at rest, wheezing and coughing, CVM said.

Severe equine asthma is associated with exposure to specific environmental triggers (e.g., dust, hay, etc.), and an affected horse may have a familial history of equine asthma.

According to CVM, Aservo EquiHaler is a non-pressurized metered dose inhaler and drug cartridge combination. The drug cartridge contains an inhalation solution that is dispensed by the inhaler into the horse’s left nostril as a spray. Each inhaler is labeled for 10 days of administration and contains sufficient drug to provide 140 actuations (puffs) to the horse. Once the inhaler has been activated, it must be used within 12 days.

CVM said the sponsor evaluated the safety and effectiveness of the product in horses with severe equine asthma in a multi-site field study involving 26 veterinary clinics in the U.S., and the data collected during the field study demonstrated that Aservo EquiHaler, when used according to the label, is safe and effective for management of clinical signs associated with severe equine asthma in horses.

The most common adverse effects found were coughing and nasal discharge. A small number of horses involved in the studies also experienced an elevated level of white blood cells (leukocytosis and/or neutrophilia), sneezing, nasal irritation or bleeding and laminitis (a painful inflammatory condition of the horse’s tissues in its hoof).

CVM said Aservo EquiHaler is available by a veterinarian’s prescription only because professional expertise is required to properly diagnose severe equine asthma and monitor safe use of the product, including treatment of any adverse reactions.

Aservo EquiHaler is manufactured by Boehringer Ingelheim Animal Health USA Inc. in Duluth, Ga.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.